Literature DB >> 27500442

Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma.

György Losonczy1.   

Abstract

Entities:  

Year:  2016        PMID： 27500442      PMCID： PMC4958793          DOI： 10.21037/jtd.2016.05.53

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  7 in total

1.  CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.

Authors:  Giulio Metro; Gianluigi Lunardi; Piero Floridi; Jennifer P Pascali; Luca Marcomigni; Rita Chiari; Vienna Ludovini; Lucio Crinò; Stefania Gori
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

2.  Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

Authors:  Kimberly L Johung; Norman Yeh; Neil B Desai; Terence M Williams; Tim Lautenschlaeger; Nils D Arvold; Matthew S Ning; Albert Attia; Christine M Lovly; Sarah Goldberg; Kathryn Beal; James B Yu; Brian D Kavanagh; Veronica L Chiang; D Ross Camidge; Joseph N Contessa
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

3.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Authors:  Luc Friboulet; Nanxin Li; Ryohei Katayama; Christian C Lee; Justin F Gainor; Adam S Crystal; Pierre-Yves Michellys; Mark M Awad; Noriko Yanagitani; Sungjoon Kim; AnneMarie C Pferdekamper; Jie Li; Shailaja Kasibhatla; Frank Sun; Xiuying Sun; Su Hua; Peter McNamara; Sidra Mahmood; Elizabeth L Lockerman; Naoya Fujita; Makoto Nishio; Jennifer L Harris; Alice T Shaw; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2014-03-27       Impact factor: 39.397

4.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

5.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

6.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

7.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.